- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc stock price live, this page displays NASDAQ PRLD stock exchange data. View the PRLD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Prelude Therapeutics Inc real time stock price chart below.
What Is the Prelude Therapeutics Inc Stock Price Today?
The Prelude Therapeutics Inc stock price today is 0.857.
What Is the Stock Symbol for Prelude Therapeutics Inc?
The stock symbol for Prelude Therapeutics Inc is ""PRLD.""
What Stock Exchange Does Prelude Therapeutics Inc Trade On?
Prelude Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Prelude Therapeutics Inc a Good Stock to Buy?
Determining whether Prelude Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRLD quote. (ISIN: US74065P1012)
What Is the Prelude Therapeutics Inc Stock Price Today?
The Prelude Therapeutics Inc stock price today is 0.857.
What Is the Stock Symbol for Prelude Therapeutics Inc?
The stock symbol for Prelude Therapeutics Inc is ""PRLD.""
What Stock Exchange Does Prelude Therapeutics Inc Trade On?
Prelude Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Prelude Therapeutics Inc a Good Stock to Buy?
Determining whether Prelude Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRLD quote. (ISIN: US74065P1012)
NASDAQ
Currency in USD
0.857
+0.007(+0.82%)
Closed·
Pre Market
0.850-0.007(-0.82%)
·
Fair Value
An estimate of a Prelude's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.838
0.910
52 wk Range
0.610
6.800
PRLD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a Prelude's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8380.910
52 wk Range
0.6106.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PRLD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Prelude's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
3.750
Upside
+337.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Prelude Therapeutics Inc Company Profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Inc SWOT Analysis
Clinical Promise | Explore Prelude Therapeutics' innovative oncology pipeline, featuring SMARCA2 degraders and CDK9 inhibitors showing early efficacy in challenging cancers |
Financial Tightrope | Delve into Prelude's financial strategy, balancing a strong cash position against ongoing R&D expenses and negative earnings projections |
Market Positioning | Uncover how Prelude navigates the competitive oncology landscape, leveraging its niche focus to potentially disrupt established treatment paradigms |
Future Catalysts | Analyst targets range from $1 to $7, with upcoming trial data and potential partnerships poised to significantly impact Prelude's market valuation |
Compare PRLD to Peers and Sector
Metrics to compare | PRLD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRLDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −1.1x | −0.5x | |
PEG Ratio | −0.04 | −0.06 | 0.00 | |
Price/Book | 0.5x | 2.2x | 2.6x | |
Price / LTM Sales | 6.9x | 9.2x | 3.3x | |
Upside (Analyst Target) | - | 308.0% | 43.4% | |
Fair Value Upside | Unlock | 18.5% | 7.1% | Unlock |
Analyst Ratings
3 Buy
0 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.750
(+337.57% Upside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-0.42 / -0.425
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Prelude Trade On?
Prelude is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Prelude?
The stock symbol for Prelude is "PRLD."
What Is the Prelude Market Cap?
As of today, Prelude market cap is 48.39M.
What Is Prelude's Earnings Per Share (TTM)?
The Prelude EPS (TTM) is -1.68.
When Is the Next Prelude Earnings Date?
Prelude will release its next earnings report on 12 Aug 2025.
From a Technical Analysis Perspective, Is PRLD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Prelude Stock Split?
Prelude has split 0 times.
How Many Employees Does Prelude Have?
Prelude has 131 employees.
What is the current trading status of Prelude (PRLD)?
As of 08 Aug 2025, Prelude (PRLD) is trading at a price of 0.86, with a previous close of 0.86. The stock has fluctuated within a day range of 0.84 to 0.91, while its 52-week range spans from 0.61 to 6.80.
What Is Prelude (PRLD) Price Target According to Analysts?
The average 12-month price target for Prelude is USD3.75, with a high estimate of USD5 and a low estimate of USD1. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +337.57% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.